Healthcare innovator Trellus Health plc has signed a 12-month contract with one of the world’s largest clinical research organisations (CROs) to use its Trellus TrialSet platform.

The agreement, focused on immunology and inflammation, aims to optimise recruitment and enrolment for two late-stage clinical trials by helping identify and support participants with lower resilience.

This is the listed firm’s second major CRO partnership and it includes upfront and milestone payments tied to participant engagement and recruitment outcomes.

It follows Trellus’s earlier Patient Support Program agreement with Johnson & Johnson.